Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy
Open Access
- 16 April 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 6155
Abstract
Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.Keywords
Funding Information
- Government of Catalonia | Departament de Salut, Generalitat de Catalunya (SLT006/17/00131)
- Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (FIS16/00627)
This publication has 14 references indexed in Scilit:
- Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathyNeurology, 2016
- Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathyNeurology, 2013
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revisionJournal of the Peripheral Nervous System, 2010
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First RevisionEuropean Journal of Neurology, 2010
- Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathyNeurology, 2009
- Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathyAnnals of Neurology, 2009
- Inter‐laboratory validation of an ELISA for the determination of serum anti‐ganglioside antibodiesEuropean Journal of Neurology, 1999
- Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathyActa Neuropathologica, 1998
- Frequency and clinical correlates of anti–neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathyAnnals of Neurology, 1994
- Neuropathy and anti‐MAG antibodies without detectable serum M‐proteinNeurology, 1984